Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma

Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma
0
(0)

Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab), according to the T-cell treatment’s developer, Adaptimmune Therapeutics.

To qualify for the study, patients’ tumor cells must express the NY-ESO or LAGE-1 proteins, or both. Expression is the process by which information from a gene is used to create a functional product like a protein.

This is the third clinical trial Adaptimune has started in a month. The company is also evaluating its AFP SPEAR T-cell therapy in hepatocellular carcinoma, the most common type of liver cancer, and its MAGE-A4 SPEAR T-cells in seven malignant solid tumors.

“We are excited to initiate this study as we have already seen encouraging data in a previous single-agent study of NY‑ESO SPEAR T-cells in patients with advanced myeloma in the context of stem cell transplantation,” Rafael Amado, Adaptimmune’s chief medical officer, said in a press release.

Keytruda, which targets the PD-1 protein associated with some cancers, has shown promise against multiple myeloma in combination with other therapies. There is preclinical-trial evidence “to support the view that the combination of NY-ESO SPEAR T-cells and anti-PD-1 therapy may lead to meaningful anti-tumor activity,” Amado said.

NY-ESO-1 is a cancer antigen, or molecule that can trigger an immune response against cancer. Researchers have found high levels of its expression in multiple myelomas that carry a bleak prognosis.

Adaptimune engineers patients’ T-cells to express a T-cell receptor that has a high affinity for — or desire to bond with — specific cancer proteins. The company calls the T-cell platform it developed SPEAR, for specific peptide enhanced affinity receptor.

It tested NYO-ESO spear in a previous Phase 1/2 single-arm clinical trial (NCT01352286) of 25 high-risk or relapsed myeloma patients with few remaining treatment options and low life expectancy. The treatment led to a complete response — or the disappearance of all signs of the cancer — in 70 percent of the patients within three months. Patients had high-dose chemotherapy and a stem cell transplant before receiving the modified T-cells.

The new open-label, randomized, pilot trial will evaluate the safety and effectiveness of NY-ESO SPEAR T-cells and Keytruda in 20 relapsed or refractory multiple myeloma patients. The 20 must express the NY-ESO-1 or LAGE-1a proteins, or both. They must also express cell-surface proteins known as HLA-A*02 that are involved in immune system regulation.

The trial participants will be randomized to receive either NY-ESO-1 alone or in a combination with Keytruda. The main objective of the study will be to determine which regimen works better.

Researchers will also be looking at the two regimens’ anti-tumor activity and how long the modified T-cells stay in the body.

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • Blenrep approved
  • COVID-19 case report
  • trial of myeloma drug Aplidin for COVID-19
  • MOR202

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?